Key result
Plasma proteomics links NT-proBNP to ~62% higher incident HCM risk in MYBPC3 carriers.
Why the study?
Hypertrophic cardiomyopathy is clinically variable in onset and progression, and pathogenic MYBPC3 variants account for a substantial proportion of diagnoses. This study sought to identify plasma protein biomarkers associated with HCM severity.
Do plasma protein biomarkers associate with hypertrophic cardiomyopathy severity in pathogenic MYBPC3 variant carriers and predict incident hypertrophic cardiomyopathy and left ventricular wall thickness in the general population?
Cohort (n=52,704)
Yes
Do plasma protein biomarkers associate with hypertrophic cardiomyopathy severity in pathogenic MYBPC3 variant carriers and predict incident hypertrophic cardiomyopathy and left ventricular wall thickness in the general population?
This study identified and replicated 21 plasma proteins associated with HCM severity and onset, prioritizing five biomarkers (NT-proBNP, GDF-15, FGF-23, ADM, and NCAM1) with potential utility for genotype-independent risk stratification, disease monitoring, and drug repurposing.
Answers are grounded in this paper and cite their sources.
May support proteomic stratification in MYBPC3 carriers; leaves open prospective validation before clinical use.
Background Hypertrophic cardiomyopathy (HCM) is a clinically variable disease in terms of onset and progression. Pathogenic MYBPC3 variants account for a substantial proportion of HCM diagnoses. This study sought to identify protein biomarkers associated with HCM severity. Methods Olink-assayed plasma proteins of 144 MYBPC3 pathogenic variant carriers were tested for associations with HCM severity based on HCM diagnostic criteria (unaffected, mildly, or severely affected). The UK Biobank was used to replicate the identified proteins through considering time to onset of HCM (67 cases), cardiomyopathy (156 cases),and associations with cardiac MRI derived left ventricular maximum wall thickness (6,492 participants). Replicated proteins were further prioritised based on cardiac tissue expression and druggability, and annotated using pathway enrichment and association with onset of: heart failure (HF), dilated cardiomyopathy (DCM), sudden cardiac arrest (SCA), and ventricular arrhythmias (VA). Results Among pathogenic MYBPC3 variant carriers, we identified 27 proteins associated with HCM severity. We independently replicated 21 proteins in the UK Biobank. Of the five prioritised proteins (NT-proBNP, GDF-15, FGF-23, ADM, and NCAM1), all but NT-proBNP were targeted by drugs with repurposing potential. The replicated proteins additionally associated with the incidence of HF (n=5), DCM (n=4), SCA (n=4), and VA (n=4). Conclusion This study replicated 21 and prioritised five proteins associated with HCM severity in pathogenic MYBPC3 variant carriers. Replication in unselected HCM suggests the prioritised proteins are associated with HCM independent of genotype, providing important leads for plasma-based markers for diagnoses, disease monitoring, and drug targets.
No takes yet. Share an insight, caveat, or question.
Hassanzada et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (HCM) and pathogenic MYBPC3 variant carriage (n=52,704). Olink-assayed plasma protein biomarkers (prioritised: NT-proBNP, GDF-15, FGF-23, ADM, and NCAM1) vs. Unaffected MYBPC3 variant carriers or lower plasma protein levels was evaluated on HCM severity in MYBPC3 carriers and time to incident HCM in the UK Biobank (reported for NT-proBNP) (HR 1.62, 95% CI 1.42-1.83). Olink plasma proteomics identified 27 proteins associated with HCM severity in MYBPC3 carriers, replicating 21 in the UK Biobank and prioritizing NT-proBNP, GDF-15, FGF-23, ADM, and NCAM1.
Synapse has enriched 10 related papers. Consider them for comparative context: